Table 2.

Rankings of different interventions

Assessments	Rankings of different interventions
MMSE	HF-rTMS[2.25(0.77,3.66)] > Dual-rTMS > LF-rTMS > a-tDCS > Dual-rTMS > Placebo
	HF-rTMS-DLPFC[2.51(0.64,4.46)] > LF-rTMS-M1 > HF-rTMS-M1 > Dual-rTMS-M1 > a-tDCS-FTP > LF-rTMS-PPC > Dual-tDCS-DLPFC > Placebo
MoCA	HF-rTMS > LF-rTMS > Placebo > c-tDCS
	HF-rTMS-DLPFC > LF-rTMS-DLPFC > Placebo > c-tDCS-M1
BI	Dual-rTMS[27.61(25.66,29.57)] > LF-rTMS[12.80(10.78,14.84)] > HF-rTMS[8.60(6.66,10.56)] > Placebo > c-tDCS
	Dual-rTMS-M1[27.61(25.66,29.57)] > LF-rTMS-M1[12.80(10.78,14.84)] > HF-rTMS-M1[8.60(6.66,10.56)] > Placebo > c-tDCS-M1
MBI	LF-rTMS[10.70(9.00,12.38)] > HF-rTMS[9.31(6.28,12.38)] > c-tDCS > a-tDCS > Placebo
	HF-rTMS-PPC[13.45(6.18,20.71)] > HF-rTMS-DLPFC[9.65(5.01,14.15)] > HF-rTMS-DLPFC[8.07(4.74,11.39)] > LF-rTMS-PPC[4.06(0.13,8.02)] > c-tDCS-PPC > a-tDCS-PPC > a-tDCS-FTP > Placebo
FIM	Dual-tDCS > cTBS > a-tDCS > HF-rTMS > LF-rTMS > Placebo
	HF-rTMS-DLPFC > Dual-tDCS-DLPFC > cTBS-PPC > a-tDCS-M1 > LF-rTMS-PPC > LF-rTMS-M1 > Placebo > HF-rTMS-M1
NIHSS	Dual-rTMS[4.90(3.53,6.29)] > LF-rTMS[2.74(1.12,4.37)] > HF-rTMS[2.09(1.37,2.81)] > a-tDCS[1.62(1.31,1.93)] > Placebo > c-tDCS
	Dual-rTMS-M1[4.95(3.20,6.70)] > LF-rTMS-M1[2.79(0.83,4.75)] > HF-rTMS-M1[2.15(0.53,3.79)] > a-tDCS-STG[1.62(1.31,1.93)] > HF-rTMS-DLPFC[2.08(1.29,2.87)] > c-tDCS-M1 > Placebo > c-tDCS-STG

HF- high frequency, LF- low frequency, cTBS continuous theta burst stimulation, a- anodal, c- cathodal, DLPFC dorsolateral prefrontal cortex, STG superior temporal gyrus, FTP fronto-temporal region, PPC posterior parietal cortex, M1 primary motor cortex, rTMS repetitive transcranial magnetic stimulation, tDCS transcranial direct current stimulation